TY - JOUR
T1 - Clinical impact of 5ʹMYC or 3ʹMYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas
AU - Tang, Guilin
AU - Li, Shaoying
AU - Toruner, Gokce A.
AU - Jain, Preetesh
AU - Tang, Zhenya
AU - Hu, Shimin
AU - Xu, Jie
AU - Cheng, Joanne
AU - Robinson, Melissa
AU - Vega, Francisco
AU - Medeiros, L. Jeffrey
N1 - Funding Information:
The Clinical Cytogenetics Laboratory for performing FISH tests, including metaphase FISH.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/4
Y1 - 2023/4
N2 - FISH analysis using MYC break-apart probes is a widely used technique to assess for MYC rearrangement (MYC-R). Occasionally, FISH results in atypical signal patterns, such as gain or loss of 5ʹMYC or 3ʹMYC. The clinical impact and/or relationship of these atypical signal patterns to MYC-R are unknown. In this study, we assessed 35 patients who had aggressive B-cell lymphomas and exhibited atypical FISH signal patterns: 3ʹMYC deletion (n = 16) or 3ʹMYC deletion plus 5ʹMYC amplification (n = 5), 5ʹMYC gain (n = 10), 5ʹMYC deletion (n = 3), and 3ʹMYC gain (n = 1). For comparison, we also included 9 patients who showed an unbalanced MYC-R. Patients with 5ʹMYC gain showed MYC expression and were often refractory to chemotherapy (n = 7) or had early relapse (n = 2). By contrast, lymphomas with 3ʹMYC deletion were negative or had low expression of MYC (16 of 18), and patients often responded to chemotherapy (16 of 19). The median event-free survival was 24, 6, and 4 months for patients with 3ʹMYC deletion, 5ʹMYC gain and unbalanced MYC-R, respectively (p = 0.0048). We conclude that 5ʹMYC gain is associated with MYC expression and a poorer prognosis and likely represents an unbalanced MYC-R. By contrast, 3ʹMYC deletions are not associated with MYC expression or a poorer prognosis and this finding may be unrelated to MYC-R.
AB - FISH analysis using MYC break-apart probes is a widely used technique to assess for MYC rearrangement (MYC-R). Occasionally, FISH results in atypical signal patterns, such as gain or loss of 5ʹMYC or 3ʹMYC. The clinical impact and/or relationship of these atypical signal patterns to MYC-R are unknown. In this study, we assessed 35 patients who had aggressive B-cell lymphomas and exhibited atypical FISH signal patterns: 3ʹMYC deletion (n = 16) or 3ʹMYC deletion plus 5ʹMYC amplification (n = 5), 5ʹMYC gain (n = 10), 5ʹMYC deletion (n = 3), and 3ʹMYC gain (n = 1). For comparison, we also included 9 patients who showed an unbalanced MYC-R. Patients with 5ʹMYC gain showed MYC expression and were often refractory to chemotherapy (n = 7) or had early relapse (n = 2). By contrast, lymphomas with 3ʹMYC deletion were negative or had low expression of MYC (16 of 18), and patients often responded to chemotherapy (16 of 19). The median event-free survival was 24, 6, and 4 months for patients with 3ʹMYC deletion, 5ʹMYC gain and unbalanced MYC-R, respectively (p = 0.0048). We conclude that 5ʹMYC gain is associated with MYC expression and a poorer prognosis and likely represents an unbalanced MYC-R. By contrast, 3ʹMYC deletions are not associated with MYC expression or a poorer prognosis and this finding may be unrelated to MYC-R.
KW - 3MYC gain/deletion
KW - 5MYC gain/deletion
KW - Aggressive B-cell lymphoma
KW - Unbalanced MYC rearrangement
UR - http://www.scopus.com/inward/record.url?scp=85145568579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145568579&partnerID=8YFLogxK
U2 - 10.1016/j.cancergen.2022.12.001
DO - 10.1016/j.cancergen.2022.12.001
M3 - Article
C2 - 36566629
AN - SCOPUS:85145568579
SN - 2210-7762
VL - 272-273
SP - 1
EP - 8
JO - Cancer Genetics
JF - Cancer Genetics
ER -